Literature DB >> 33882289

Vaginal Squamous Cell Carcinoma Develops in Mice with Conditional Arid1a Loss and Gain of Oncogenic Kras Driven by Progesterone Receptor Cre.

Xiyin Wang1, Mariana S L Praça1, Jillian R H Wendel1, Robert E Emerson2, Francesco J DeMayo3, John P Lydon4, Shannon M Hawkins5.   

Abstract

Oncogenic KRAS mutations are a common finding in endometrial cancers. Recent sequencing studies indicate that loss-of-function mutations in the ARID1A gene are enriched in gynecologic malignant tumors. However, neither of these genetic insults alone are sufficient to develop gynecologic cancer. To determine the role of the combined effects of deletion of Arid1a and oncogenic Kras, Arid1aflox/flox mice were crossed with KrasLox-Stop-Lox-G12D/+ mice using progesterone receptor Cre (PgrCre/+). Histologic analysis and immunohistochemistry of survival studies were used to characterize the mutant mouse phenotype. Hormone dependence was evaluated by ovarian hormone depletion and estradiol replacement. Arid1aflox/flox; KrasLox-Stop-Lox-G12D/+; PgrCre/+ mice were euthanized early because of invasive vaginal squamous cell carcinoma. Younger mice had precancerous intraepithelial lesions. Immunohistochemistry supported the pathological diagnosis with abnormal expression and localization of cytokeratin 5, tumor protein P63, cyclin-dependent kinase inhibitor 2A, and Ki-67, the marker of proliferation. Ovarian hormone deletion in Arid1aflox/flox; KrasLox-Stop-Lox-G12D/+; PgrCre/+ mice resulted in atrophic vaginal epithelium without evidence of vaginal tumors. Estradiol replacement in ovarian hormone-depleted Arid1aflox/flox; KrasLox-Stop-Lox-G12D/+; PgrCre/+ mice resulted in lesions that resembled the squamous cell carcinoma in intact mice. Therefore, this mouse can be used to study the transition from benign precursor lesions into invasive vaginal human papillomavirus-independent squamous cell carcinoma, offering insights into progression and pathogenesis of this rare disease.
Copyright © 2021 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33882289      PMCID: PMC8261476          DOI: 10.1016/j.ajpath.2021.03.013

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   5.770


  60 in total

1.  ARID1A suppresses malignant transformation of human pancreatic cells via mediating senescence-associated miR-503/CDKN2A regulatory axis.

Authors:  Zhao-Yun Li; Shan-Shan Zhu; Xian-Jun Chen; Jie Zhu; Qi Chen; Ya-Qiong Zhang; Chun-Ling Zhang; Ting-Ting Guo; Li-Ming Zhang
Journal:  Biochem Biophys Res Commun       Date:  2017-09-20       Impact factor: 3.575

2.  Subcellular localization, modification and protein complex formation of the cdk-inhibitor p16 in Rb-functional and Rb-inactivated tumor cells.

Authors:  Kristina Nilsson; Göran Landberg
Journal:  Int J Cancer       Date:  2006-03-01       Impact factor: 7.396

3.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

4.  A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells.

Authors:  Raluca A Budiu; Iulia Diaconu; Rachel Chrissluis; Anica Dricu; Robert P Edwards; Anda M Vlad
Journal:  Dis Model Mech       Date:  2009-10-19       Impact factor: 5.758

5.  Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas.

Authors:  K Evangelou; J Bramis; I Peros; P Zacharatos; D Dasiou-Plakida; N Kalogeropoulos; P J Asimacopoulos; C Kittas; E Marinos; V G Gorgoulis
Journal:  Biotech Histochem       Date:  2004-02       Impact factor: 1.718

6.  Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells.

Authors:  Heng-Yu Fan; Zhilin Liu; Marilene Paquet; Jinrong Wang; John P Lydon; Francesco J DeMayo; JoAnne S Richards
Journal:  Cancer Res       Date:  2009-08-15       Impact factor: 12.701

7.  Pten and Dicer1 loss in the mouse uterus causes poorly differentiated endometrial adenocarcinoma.

Authors:  Xiyin Wang; Jillian R H Wendel; Robert E Emerson; Russell R Broaddus; Chad J Creighton; Douglas B Rusch; Aaron Buechlein; Francesco J DeMayo; John P Lydon; Shannon M Hawkins
Journal:  Oncogene       Date:  2020-08-25       Impact factor: 9.867

8.  ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion.

Authors:  Mike R Wilson; Jake J Reske; Jeanne Holladay; Genna E Wilber; Mary Rhodes; Julie Koeman; Marie Adams; Ben Johnson; Ren-Wei Su; Niraj R Joshi; Amanda L Patterson; Hui Shen; Richard E Leach; Jose M Teixeira; Asgerally T Fazleabas; Ronald L Chandler
Journal:  Nat Commun       Date:  2019-08-07       Impact factor: 14.919

9.  The Synergistic Effect of Conditional Pten Loss and Oncogenic K-ras Mutation on Endometrial Cancer Development Occurs via Decreased Progesterone Receptor Action.

Authors:  Tae Hoon Kim; Jinrong Wang; Kevin Y Lee; Heather L Franco; Russell R Broaddus; John P Lydon; Jae-Wook Jeong; Francesco J Demayo
Journal:  J Oncol       Date:  2009-10-27       Impact factor: 4.375

10.  Topical KGF treatment as a therapeutic strategy for vaginal atrophy in a model of ovariectomized mice.

Authors:  Simona Ceccarelli; Sirio D'Amici; Enrica Vescarelli; Paolo Coluccio; Pietro Matricardi; Cira di Gioia; Pierluigi Benedetti Panici; Ferdinando Romano; Luigi Frati; Antonio Angeloni; Cinzia Marchese
Journal:  J Cell Mol Med       Date:  2014-08-01       Impact factor: 5.310

View more
  2 in total

1.  Sex-dependent development of Kras-induced anal squamous cell carcinoma in mice.

Authors:  Morgan T Walcheck; Kristina A Matkowskyj; Anne Turco; Simon Blaine-Sauer; Manabu Nukaya; Jessica Noel; Oline K Ronnekleiv; Sean M Ronnekleiv-Kelly
Journal:  PLoS One       Date:  2021-11-04       Impact factor: 3.240

2.  Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.

Authors:  Jake J Reske; Mike R Wilson; Jeanne Holladay; Rebecca A Siwicki; Hilary Skalski; Shannon Harkins; Marie Adams; John I Risinger; Galen Hostetter; Ken Lin; Ronald L Chandler
Journal:  PLoS Genet       Date:  2021-12-23       Impact factor: 5.917

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.